The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 24, 2015
Filed:
Sep. 12, 2012
Applicants:
Francesco Tedesco, Trieste, IT;
Roberto Marzari, Trieste, IT;
Inventors:
Francesco Tedesco, Trieste, IT;
Roberto Marzari, Trieste, IT;
Assignee:
Adienne S.A., Lugano, CH;
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/13 (2006.01); C12N 15/00 (2006.01); C12N 15/11 (2006.01); C07K 16/18 (2006.01); C12N 15/62 (2006.01); C12N 15/70 (2006.01); C12N 15/85 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/11 (2013.01); C07K 16/18 (2013.01); C12N 15/62 (2013.01); C12N 15/70 (2013.01); C12N 15/85 (2013.01); A61K 2039/505 (2013.01); C07K 2316/96 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/622 (2013.01); C07K 2317/92 (2013.01); C07K 2319/00 (2013.01); C07K 2317/52 (2013.01);
Abstract
The present invention refers to recombinant antibodies of human origin specific for the C5 component of the activated complement and characterised by the ability to inhibit the conversion of the C5 alpha chain to C5a and C5b. Moreover the present invention refers to the nucleotide sequences coding for such antibodies and to the therapeutic use of both polypeptide and nucleotide sequences, in particular for the therapy of diseases involving tissue damage deriving from uncontrolled activation of the complement system.